Table 1.
Baseline Characteristics of the Pediatric Cohort Undergoing Allogeneic Hematopoietic Cell Transplantation (n=76)
| Variables | N (%) | |
|---|---|---|
| Median age at transplantation, year (range) | 7 (2–18) | |
| Age groups (years) | 2–4 | 24 (32) |
| 5–7 | 20 (27) | |
| 8–12 | 18 (24) | |
| 13–18 | 14 (18) | |
| Sex | Male | 42 (55) |
| Female | 34 (45) | |
| Race | White/ Caucasian | 62 (82) |
| Other | 13 (17) | |
| Unknown/ declined | 1 (1) | |
| Karnofsky/ Lansky score | ≥ 90 | 67 (88) |
| < 90 | 9 (12) | |
| HCT-comorbidity index | 0 | 52 (68) |
| ≥ 1 | 22 (29) | |
| Missing | 2 (3) | |
| Annual household income | < $20,000 | 15 (20) |
| $20,000– $39,999 | 11 (14) | |
| $40,000– $59,999 | 6 (8) | |
| $60,000– $79,999 | 9 (12) | |
| $80,000– $99,999 | 7 (9) | |
| ≥ $100,000 | 13 (17) | |
| Unknown/ Declined | 15 (20) | |
| Disease type | Malignant | 33 (43) |
| Non-malignant | 43 (57) | |
| Stem cell source | Bone marrow | 45 (60) |
| Peripheral blood | 20 (26) | |
| Cord blood | 11 (14) | |
| TBI use | No | 50 (66) |
| < 1200 cGy | 20 (26) | |
| ≥ 1200 cGy | 6 (8) | |
| Conditioning regimen | Myeloablative | 55 (72) |
| Reduced intensity/ Non-myeloablative | 21 (28) | |
| Graft vs. host disease prophylaxis | CNI + MMF ± other(s) | 12 (16) |
| CNI + MTX ± other(s) | 23 (30) | |
| CNI ± other(s) (not MMF or MTX) | 26 (34) | |
| Ex-vivo T-cell depletion/ CD34 selection | 14 (18) | |
| Unknown | 1 (1) | |
| Year of transplant | 2011 | 9 (12) |
| 2012 | 50 (66) | |
| 2013 | 17 (22) | |
| Median follow-up of survivors, months (range) | 24 (3–46) | |
| Post-HCT complications | Acute graft vs. host disease | 30 (39) |
| Chronic graft vs. host disease | 15 (20) | |
| Relapse/ progression (malignant diseases only) | 7 (21) |
HCT- hematopoietic cell transplant, TBI- total body irradiation, CNI- calcineurin inhibitor, MMF- mycophenolate mofetil, MTX- methotrexate